A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2001-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1136/jnnp.70.6.773PMID 11385012PMCID PMC1737379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple Sclerosis

  2007cited by this paper
• A Replicated Prospective Investigation of Life Stress, Coping, and Depressive Symptoms in Multiple Sclerosis

  2004cited by this paper
• Studies of Interference in Serial Verbal Reactions

  2001cited by this paper
• Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis

  2000cited by this paper
• A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis

  2000cited by this paper
• Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a

  2000cited by this paper
• Progressive cerebral atrophy in MS

  2000cited by this paper
• MRI correlates of cognitive dysfunction in multiple sclerosis patients.

  2000cited by this paper
• Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.

  2000cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

  2000cited by this paper
• Magnetization transfer ratio in new MS lesions before and during therapy with IFN&bgr;‐1a

  2000cited by this paper
• Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis.

  2000cited by this paper
• Neuropsychological effects of interferon β‐1a in relapsing multiple sclerosis

  2000cited by this paper
• Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS

  2000cited by this paper
• Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI

  2000cited by this paper
• Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.

  1999cited by this paper
• Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

  1999influential reference
• Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology.

  1999cited by this paper
• Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.

  1999cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.

  1999cited by this paper
• Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study.

  1999cited by this paper
• Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

  1999cited by this paper
• Memory dysfunction in multiple sclerosis corresponds to juxtacortical lesion load on fast fluid-attenuated inversion-recovery MR images.

  1999cited by this paper
• Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI

  1999cited by this paper
• A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis.

  1999cited by this paper
• MR lesion load and cognitive function in patients with relapsing-remitting multiple sclerosis.

  1999cited by this paper
• Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.

  1999cited by this paper
• Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis.

  1999cited by this paper
• Magnetization transfer imaging to monitor clinical trials in multiple sclerosis.

  1999cited by this paper
• A multiparametric MRI study of frontal lobe dementia in multiple sclerosis.

  1999cited by this paper
• Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial

  1999cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis

  1999cited by this paper
• Pediatric migraine and the International Headache Society criteria

  1998cited by this paper
• Correlation of volumetric magnetization transfer imaging with clinical data in MS

  1998cited by this paper
• AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS

  1998cited by this paper
• Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow‐up study

  1998cited by this paper
• Neurophysiological and cognitive markers of disease evolution in multiple sclerosis

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

  1998cited by this paper
• Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis

  1998cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

  1998cited by this paper
• Isolated U-fiber involvement in MS

  1998cited by this paper
• Pediatric migraine and the International Headache Society (IHS) criteria

  1997cited by this paper
• Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

  1997cited by this paper
• Axonal damage in acute multiple sclerosis lesions.

  1997cited by this paper
• Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

  1997cited by this paper
• Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

  1996cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

  1996cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up.

  1995cited by this paper
• A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis.

  1993cited by this paper
• Serial study of neuropsychological performance and gadolinium‐enhanced MRI in MS

  1993cited by this paper
• Acute optic neuritis : a cognitive and magnetic resonance imaging study

  1992cited by this paper
• Cognitive dysfunction in multiple sclerosis.

  1991cited by this paper
• Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

  1991influential reference
• Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging

  1991cited by this paper
• Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination.

  1990cited by this paper
• Cognitive Neuropsychology: A Clinical Introduction

  1990cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion

  1977cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975influential reference
• Development of a rating scale for primary depressive illness.

  1967cited by this paper
• The assessment of anxiety states by rating.

  1959cited by this paper
• Manual for the Wechsler Adult Intelligence Scale.

  1955cited by this paper

• A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis

  2025cites this paper
• Norma Latina Neuropsychological Evaluation in Individuals with Multiple Sclerosis and Its Relationship with Disability

  2025cites this paper
• Longitudinal Study of Cognitive Phenotypes in Patients with Relapsing-Remitting Multiple Sclerosis.

  2025cites this paper
• Cognitive dysfunction and atrophic changes of selected cerebral structures in patients with relapsing-remitting multiple sclerosis

  2025cites this paper
• Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis

  2024cites this paper
• Optimizing Detection and Prediction of Cognitive Function in Multiple Sclerosis With Ambulatory Cognitive Tests: Protocol for the Longitudinal Observational CogDetect-MS Study

  2024cites this paper
• Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis

  2024cites this paper
• Mapping brain volume change across time in primary-progressive multiple sclerosis

  2024cites this paper
• Impairments of attention in RRMS patients: the role of disease duration

  2024influential citation
• Cognitive Impairment in Multiple Sclerosis: Past, Present, and Future.

  2024cites this paper
• Serum neurofilament light chains in progressive multiple sclerosis patients treated with repeated cycles of high-dose intravenous steroids.

  2023cites this paper
• Basal Ganglia Atrophy as a Marker of Multiple Sclerosis Progression

  2023cites this paper
• Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis

  2023cites this paper
• Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.

  2023cites this paper
• Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics

  2022cites this paper
• Thalamic atrophy, duration of illness, and years of education are the best predictors of cognitive impairment in multiple sclerosis

  2022cites this paper
• Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study.

  2022cites this paper
• A Distinct Hibiscus sabdariffa Extract Prevents Iron Neurotoxicity, a Driver of Multiple Sclerosis Pathology

  2022cites this paper
• Evaluation of leptomeningeal enhancement in patients with multiple sclerosis

  2022influential citation
• Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis

  2022cites this paper
• Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure

  2022cites this paper
• Prediction of the information processing speed performance in multiple sclerosis using a machine learning approach in a large multicenter magnetic resonance imaging data set

  2022cites this paper
• Barriers to quality of life in patients with multiple sclerosis: a qualitative study

  2022cites this paper
• Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS - A longitudinal correlation study.

  2022cites this paper
• Patterns of brain degeneration in early-stage relapsing-remitting multiple sclerosis

  2022cites this paper
• The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective.

  2021cites this paper
• Telephone-based assessment of multiple sclerosis patients at Ain Shams University Hospital in the coronavirus disease 2019 pandemic

  2021cites this paper
• Cognitive trajectories in multiple sclerosis: a long-term follow-up study

  2021cites this paper
• Patterns of brain neurodegeneration in early-stage relapsing-remitting multiple sclerosis

  2021cites this paper
• Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis

  2021cites this paper
• 7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions

  2021cites this paper
• The effects of aging and disease duration on cognition in multiple sclerosis.

  2020cites this paper
• Cognitive trajectories in relapsing–remitting multiple sclerosis: A longitudinal 6-year study

  2020cites this paper
• Comorbidity effect on processing speed test and MRI measures in multiple sclerosis patients.

  2020cites this paper
• Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?

  2020cites this paper
• Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis

  2020cites this paper
• Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.

  2020cites this paper
• Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis

  2020cites this paper
• Reduced neurite density in the brain and cervical spinal cord in relapsing–remitting multiple sclerosis: A NODDI study

  2020cites this paper
• Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy

  2020cites this paper
• Clinically reliable cognitive decline in relapsing remitting multiple sclerosis: Is it the tip of the iceberg?

  2020influential citation
• Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

  2019cites this paper
• Predicting clinical progression in multiple sclerosis after 6 and 12 years

  2019cites this paper
• The Diagnostic Role of Brain MRI in Detection of Multiple Sclerosis Related Cognitive Impairment

  2019cites this paper
• Brain volume loss and no evidence of disease activity over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment.

  2019cites this paper
• Biomarkers and Disease Activity in Multiple Sclerosis : A cohort study on patients with clinically isolated syndrome and relapsing remitting multiple sclerosis

  2019cites this paper
• Clinical efficacy and safety of alemtuzumab in postmarketing practice

  2019cites this paper
• Psychoemotional reactions at the stage of clinically isolated multiple sclerosis syndrome

  2019cites this paper
• Quantitative magnetic resonance assessment of brain atrophy related to selected aspects of disability in patients with multiple sclerosis: preliminary results

  2019cites this paper
• Does multiple sclerosis cause progressive and widespread cognitive decline

  2019cites this paper
• Clinical relevance of brain atrophy measures in multiple sclerosis

  2019cites this paper
• Cognitive functions and disability progression in relapsing-remitting multiple sclerosis: A longitudinal study

  2019cites this paper
• Consensus recommendations on the management of multiple sclerosis patients in Argentina.

  2019cites this paper
• Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

  2019cites this paper
• Single MRI‐Based Volumetric Assessment in Clinical Practice Is Associated With MS‐Related Disability

  2018cites this paper
• Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis

  2018cites this paper
• Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

  2018cites this paper
• Protective Effect of Human Leukocyte Antigen (HLA) Allele DRB1*13:02 on Age-Related Brain Gray Matter Volume Reduction in Healthy Women

  2018cites this paper
• Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.

  2018cites this paper
• Marijuana Use in an Aging Population: Global Brain Structure and Cognitive Function

  2018cites this paper
• Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study

  2018cites this paper
• Automatic Identification and Characterization of White Matter Lesions in the brain using Volumetric Magnetic Resonance Images Identificação Automática e Caracterização de Lesões em Substância Branca no Cérebro em Imagens Volumétricas de Ressonância Magnética

  2017cites this paper
• Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis

  2017cites this paper
• Cognitive clinico‐radiological paradox in early stages of multiple sclerosis

  2017cites this paper
• Alemtuzumab CARE-MS II 5-year follow-up

  2017cites this paper
• 13 Multimodal MRI of Cerebral Small Vessel Disease

  2017cites this paper
• Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis

  2017cites this paper
• Effect of Fatigue, Depression and Cognitive Dysfunction on Participation in Leisurely Activities among People with Multiple Sclerosis

  2017cites this paper
• Cerebellar lobule atrophy and disability in progressive MS

  2017cites this paper
• Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

  2017cites this paper
• Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

  2017cites this paper
• Therapie der primär und sekundär chronisch-progredienten MS

  2017influential citation
• A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.

  2017cites this paper
• Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

  2017cites this paper
• Retinal measures correlate with cognitive and physical disability in early multiple sclerosis

  2016cites this paper
• Cognitive impairment in MS: rehabilitation approaches

  2016cites this paper
• Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis

  2016cites this paper
• Causes, effects and connectivity changes in MS-related cognitive decline

  2016cites this paper
• Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis

  2016cites this paper
• Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis

  2016cites this paper
• The Growing Potential of Neurophysiology in Multiple Sclerosis

  2016cites this paper
• Longitudinal study of cognitive changes in MS – dimensionality, predictors and self-perception of change

  2016cites this paper
• Longitudinal associations between MRI and cognitive changes in very early MS.

  2016cites this paper
• Multi-parametric structural MRI in relation to cognitive dysfunction in long-standing multiple sclerosis

  2016cites this paper
• A Randomised Controlled Trial of Efficacy of Cognitive Rehabilitation in Multiple Sclerosis: A Cognitive, Behavioural, and MRI Study

  2016cites this paper
• Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study

  2016cites this paper
• Neural correlates of cognitive impairment in patients with multiple sclerosis

  2016cites this paper
• Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment

  2016cites this paper
• Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression

  2016cites this paper
• Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

  2016cites this paper
• Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis

  2016cites this paper
• The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS

  2016cites this paper
• Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.

  2016cites this paper
• MRI‐Based Measurement of Brain Stem Cross‐Sectional Area in Relapsing‐Remitting Multiple Sclerosis

  2015cites this paper
• Cognitive impairment and memory disorders in relapsing–remitting multiple sclerosis: the role of white matter, gray matter and hippocampus

  2015cites this paper
• Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients

  2015cites this paper
• Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis

  2015cites this paper
• Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact

  2015cites this paper
• Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily

  2015cites this paper
• Brain atrophy in Multiple Sclerosis

  2015cites this paper